The Latest Breaking News from Veracyte

A Relative Strength Rating upgrade for Veracyte shows improving technical performance.

Veracyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 81.

On Tuesday, Veracyte got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96.

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Veracyte (VCYT) exceeded Wall Street’s expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out….

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.

Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:

Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 16.67%, reporting an EPS of $-0.2 versus an estimate of $-0.24.